Role of mTOR in glioblastoma

Gene

Volumn 575, Issue 2, 2016, Pages 187-190

  Duzgun, Zekeriya ^a   Eroglu, Zuhal ^a   Biray Avci, Cigir ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Brain tumors; Glioblastoma; MTOR signaling; PI3K AKT mTOR pathway

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; TUMOR PROTEIN;

BRAIN; CELL GROWTH; CELL PROLIFERATION; GLIOBLASTOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; GLIOBLASTOMA; HUMANS; MULTIPROTEIN COMPLEXES; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84947867105     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.08.060     Document Type: Review

References (40)

1. Akhavan D., Cloughesy T.F., Mischel P.S. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro-Oncology 2010, 12(8):882-889.
2. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., Schreiber S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369(6483):756-758.
3. Chiang G.G., Abraham R.T. Targeting the mTOR signaling network in cancer. Trends Mol. Med. 2007, 13(10):433-442.
4. Crino P.B. mTOR: a pathogenic signaling pathway in developmental brain malformations. Trends Mol. Med. 2011, 17(12):734-742.
5. Cui Y.H., Chen J., Xu T., Tian H.L. Structure-based grafting and identification of kinase-inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma. Comput. Biol. Chem. 2015, 54:57-65. 10.1016/j.compbiolchem.2015.01.001.
6. del Alcazar C.R.G., Hardebeck M.C., Mukherjee B., Tomimatsu N., Gao X., Yan J., Habib A.A. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin. Cancer Res. 2014, 20(5):1235-1248.
7. Fan Q.-W., Knight Z.A., Goldenberg D.D., Yu W., Mostov K.E., Stokoe D., Weiss W.A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006, 9(5):341-349.
8. Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z.A., Ruggero D., Shokat K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 7(2).
9. Feng Z., Zhang H., Levine A.J., Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(23):8204-8209.
10. Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A., Brennan C. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007, 21(21):2683-2710.
11. Gini B., Zanca C., Guo D., Matsutani T., Masui K., Ikegami S., Shackelford D. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin. Cancer Res. 2013, 19(20):5722-5732.
12. Grogan P.T., Sarkaria J.N., Timmermann B.N., Cohen M.S. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Investig. New Drugs 2014, 32(4):604-617.
13. Grzmil M., Hemmings B.A. Overcoming resistance to rapalogs in gliomas by combinatory therapies. Biochim. Biophys. Acta 2013, 1834(7):1371-1380. 10.1016/j.bbapap.2013.01.041.
14. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12(1):9-22.
15. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004, 18(16):1926-1945.
16. Inoki K., Li Y., Xu T., Guan K.-L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003, 17(15):1829-1834.
17. Jhanwar-Uniyal M., Labagnara M., Friedman M., Kwasnicki A., Murali R. Glioblastoma: molecular pathways, stem cells and therapeutic targets. Cancers (Basel) 2015, 7(2):538-555. 10.3390/cancers7020538.
18. Jhanwar-Uniyal M., Jeevan D., Neil J., Shannon C., Albert L., Murali R. Deconstructing mTOR complexes in regulation of glioblastoma multiforme and its stem cells. Adv. Biol. Regul. 2013, 53(2):202-210.
19. Kanu O.O., Mehta A., Di C., Lin N., Bortoff K., Bigner D.D., Adamson D.C. Glioblastoma Multiforme: A Review of Therapeutic Targets 2009.
20. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149(2):274-293. 10.1016/j.cell.2012.03.017.
21. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 2009, 10(5):307-318.
22. Mineo J.-F., Bordron A., Baroncini M., Ramirez C., Maurage C.-A., Blond S., Dam-Hieu P. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir. 2007, 149(3):245-253.
23. Mita M.M., Mita A., Rowinsky E.K. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol. Ther. 2003, 2(4; SUPP/1):S169-S177.
24. Neasta J., Hamida S.B., Yowell Q., Carnicella S., Ron D. Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders. Proc. Natl. Acad. Sci. 2010, 107(46):20093-20098.
25. Osborne L.R. Caveat mTOR: aberrant signaling disrupts corticogenesis. J. Clin. Invest. 2010, 120(5):1392-1395. 10.1172/JCI43030.
26. Pike K.G., Malagu K., Hummersone M.G., Menear K.A., Duggan H.M.E., Gomez S., Pass M. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg. Med. Chem. Lett. 2013, 23(5):1212-1216. 10.1016/j.bmcl.2013.01.019.
27. Prasad G., Sottero T., Yang X., Mueller S., James C.D., Weiss W.A., Aftab D.T. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro-Oncology 2011, 13(4):384-392.
28. Rajasekhar V.K., Viale A., Socci N.D., Wiedmann M., Hu X., Holland E.C. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell 2003, 12(4):889-901.
29. Sabatini D.M., Erdjument-Bromage H., Lui M., Tempst P., Snyder S.H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994, 78(1):35-43.
30. Sarker D., Reid A.H.M., Yap T.A., de Bono J.S. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin. Cancer Res. 2009, 15(15):4799-4805.
31. Shao T., Liu X. Identification of rictor as a novel substrate of Polo-like kinase 1. Cell Cycle 2015, 14(5):755-760. 10.1080/15384101.2014.998050.
32. Sharp Z.D., Bartke A. Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice. J. Gerontol. A: Biol. Med. Sci. 2005, 60(3):293-300.
33. Shaw R.J., Cantley L.C. Ras, PI (3) K and mTOR signalling controls tumour cell growth. Nature 2006, 441(7092):424-430.
34. Syed D.N., Adhami V.M., Khan M.I., Mukhtar H. Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin. Anti Cancer Agents Med. Chem. 2013, 13(7):995-1001.
35. Tanaka K., Sasayama T., Irino Y., Takata K., Nagashima H., Masui K., Kohmura E. NT-39 GLUTAMINASE-MEDIATED METABOLIC PATHWAY INVOLVES GLIOBLASTOMA RESISTANCE TO mTOR-TARGETED THERAPIES. Neuro-Oncology 2014, 16(Suppl. 5):v167-v167.
36. Urbanska M., Gozdz A., Swiech L.J., Jaworski J. Mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons. J. Biol. Chem. 2012, 287(36):30240-30256. 10.1074/jbc.M112.374405.
37. Wang M.Y., Lu K.V., Zhu S., Dia E.Q., Vivanco I., Shackleford G.M., Sawyers C.L. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 2006, 66(16):7864-7869.
38. Weiss W.A., Wong R., Fan Q.-W., Ilkhanizadeh S., Lu M., Beyer J., Xu T. MTOR KINASE INHIBITORS AND APOPTOSIS IN GLIOBLASTOMA. Neuro-Oncology 2014, 16(Suppl. 3). iii31-iii31.
39. Wu S.-H., Bi J.-F., Cloughesy T., Cavenee W.K., Mischel P.S. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biol. Med. 2014, 11(4):255.
40. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12(1):21-35. 10.1038/nrm3025.